(Q35627633)

9 August 2017

1 reference

title

Management of community-acquired pneumonia: a focus on conversion from hospital to the ambulatory setting (English)

1 reference

9 August 2017

2

Thomas M File

1 reference

9 August 2017

1

James S Tan

1 reference

9 August 2017

publication date

1 January 2003

1 reference

Treatments in Respiratory Medicine

9 August 2017

published in

1 reference

9 August 2017

volume

2

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

385-394

1 reference

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Implementation of admission decision support for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Quality of care, process, and outcomes in elderly patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Community-acquired pneumonia. A prospective outpatient study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Increased resistance to penicillin of pneumococci isolated from man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Antimicrobial Resistance in Streptococcus pneumoniae: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Penicillin-binding protein families: evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Effect of beta lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Mechanisms of action of antimicrobials: focus on fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

The role of atypical pathogens in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

The emerging role of atypical pathogens in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Evaluation of a pneumonia practice guideline in an interventional trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

The utility of an in-hospital observation period after discontinuing intravenous antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

Strategies for early discharge of the hospitalized patient with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256666

21 January 2018

Identifiers

DOI

10.1007/BF03256666

1 reference

9 August 2017

1 reference